Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist.

Clicks: 49
ID: 279216
2018
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Abstract is not available for this article.
Login to Search Abstract
Reference Key
bethel2018classcirculation Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Bethel, M Angelyn;McMurray, John J V;
Journal Circulation
Year 2018
DOI
10.1161/CIRCULATIONAHA.117.030117
URL
Keywords
diabetes mellitus mortality empagliflozin myocardial infarction cardiovascular diseases canagliflozin sglt-2 inhibitor

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.